Proceedings: Some considerations in the design of substrate and tissue specific inhibitors of MAO.
D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004357:Drug Synergism; D008996:Monoamine Oxidase Inhibitors / Q000138:chemical synthesis* / Q000378:metabolism; D009928:Organ Specificity; D010293:Pargyline / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism; D013329:Structure-Activity Relationship
D008996:Monoamine Oxidase Inhibitors; D012701:Serotonin; D004295:Dihydroxyphenylalanine; D010293:Pargyline